Top Tweets for #IndSwiftLaboratories
To every pharmacist making a difference, one prescription and one patient at a time — thank you for your dedication and care.
Happy World Pharmacists Day!
#WorldPharmacistsDay #PharmacistsDay #IndSwiftLaboratories #PharmaIndustry #Healthcare #Pharmacists #ReliableMedicines
Better business starts with a smarter way to order. 💙
#SwiftPlus #IndSwift #IndSwiftLaboratories #Pharmacy #PharmacyRetailer #PharmacyStockist #Chemist #PharmacyBusiness #PharmaIndustry #PharmaRetail #SmartOrdering #PharmacyApp #BusinessRewards #PharmaBusiness
#IndSwiftLaboratories Ltd Created a New 52Week High of ₹412.00 on #NSE & ₹412.20 on #BSE Today
#StockToWatch
#StockInNews
#StockInFocus
#StockMarket
#Nifty #NSE #Nifty50 #Sensex
#Indswiftlaboratories
Ind-swift laboratories Ltd at 54x P/E: - Can a massive 3.5x stock rally still leave a company fairly priced?
Evaluating the valuation based growth , risk profile and quality of growth
1. Risk Profile (Decreasing Systematic Risk)
Historically, the company commanded a distressed single-digit P/E multiple (under 3x in FY24–FY25) due to extreme financial risk.
Financial Risk (Drastic Reduction): By executing the ₹1,650 crore slump sale of its bulk API and CRAMS business, the company cleared its legacy debt overhang, turning net-debt-free. Eliminating debt significantly reduced the company's cost of capital, providing a fundamental justification for expanding its P/E multiple.
Corporate Governance & Restructuring Risk: Moving away from complicated inter-group transactions and completing the legal NCLT merger with Ind-Swift Limited in late 2025 simplified the corporate structure. Lower structural complexity reduces the "small-cap governance discount."
Regulatory Risk: Operating a 100% export facility comes with the threat of US-FDA, EU-GMP, or MHRA non-compliance warnings. While this risk is persistent in pharma, it is structurally managed through proactive plant upgrades
2. Earnings Growth (Strong Momentum)
The current high trailing P/E multiple reflects a massive, positive inflection point in corporate earnings:
The Post-Restructuring Turnaround: While the accounting profit after tax (PAT) for the trailing twelve months (TTM) sat at ~₹57 crore, recent quarterly trajectories show explosive momentum. For instance, June 2026 (Q1 FY27) quarterly net profit surged by 201% YoY to ₹24 crore.
Forward Revenue & PAT Anchors: The market is pricing the stock based on its near-term management guidance targeting ₹900 crore revenue for FY27 and ₹1,500 crore revenue / ₹200 crore PAT by FY30.
If the company achieves its ₹200 crore PAT target by FY30, the forward P/E multiple collapses to an attractive valuation relative to the current market capitalization, indicating that the market is aggressively paying upfront for visible forward growth.
3. Quality of Growth
Economic Moat
Pricing Power & Substitution Risk: The business model transitioned away from low-margin commodity API contract execution to an IP-led Finished Dosage Formulation (FDF) platform owning over 2,100 global dossiers. Controlling product dossiers allows the company to partner directly with global multi-nationals (like Viatris and Manx), locking in recurring supply agreements that insulate against standard generic pricing erosion.
Barriers to Entry: High. Transitioning a production facility to comply with EU-GMP and PIC/S standards requires multi-year lead times and steep regulatory validation hurdles.
Competitive Advantage:
Due to its asset-light formulation sourcing and co-funded customer R&D, operating margins structurally expanded to 17.91% EBITDA. Current metrics show a massive jump in asset efficiency, with a Return on Capital Employed (ROCE) of ~25.18%
Efficient Working Capital Cycle
Structural Improvement: Moving into long-term strategic CDMO supply partnerships introduces rigid commercial terms and milestone payments. Furthermore, by utilizing a customer-funded R&D blueprint where international buyers pay for molecule development costs upfront, Ind-Swift reduces the strain on its working capital. This structural shift allows earnings to convert cleanly into free cash flow rather than getting trapped in inventory or receivables.
Valuation Assessment:
Ind-Swift’s current P/E multiple of ~54x is not cheap; it sits at a minor premium.
However, this multiple is fundamentally supported rather than purely speculative. The combination of a repaired balance sheet (risk reduction), robust quarterly growth metrics exceeding 200% (earnings growth), an IP-driven dossier library (economic moat), and a 25%+ ROCE (quality of growth) explains why the market re-rated the stock.
The company transitioned from a risky micro-cap play into an execution-driven compounding candidate where future stock returns depend entirely on meeting its FY30 targets of ₹1,500 crore revenue and ₹200 crore PAT.Because the market has already priced in the initial post-merger turnaround, the current premium valuation leaves no room for operational errors.
Further re-rating can only be unlocked by tangible new triggers:
- Gaining strict EU-GMP approval for the upgraded Samba plant. (180 cr revenue potential)
- Signing large-scale multi-year CDMO order books beyond existing clients.
- Successfully monetizing its 2,100+ global product dossiers into recurring, high-margin export revenue.
- New capex that will expand revenues beyond FY30.
[Not investment advice, DYOR]
#IndswiftLaboratories
What a baseeee📈😱
- 21 years Base - Breakout + good Earnings
- Will be on Priority WL
#IndswiftLaboratories
What a baseeee📈😱
- 21 years Base - Breakout + good Earnings
- Will be on Priority WL
#IndSwiftLaboratories Ltd Created a new 52Week High of 149.90 on #NSE & 150.00 on #BSE Today
#IndSwiftLab
#StockToWatch
#StockInNews
#StockInFocus
#StockMarket
#Nifty #NSE #BSE #Nifty50 #Sensex
Ind Swift Laboratories Limited inaugurates a new marketing office at Nehru Place, New Delhi
#IndSwiftLaboratories #NewMarketingOffice #NewDelhi
https://t.co/FVO2mu4RzU
#IndiaResurgenceFund (#IndiaRF), an #India-focused distressed and special situations investment platform sponsored by the #PiramalGroup and #BainCapitalCredit, is in talks to acquire the #API business of the debt ridden #IndSwiftLaboratories
https://t.co/Nn2BmNEnQO
Ind-Swift Laboratories wins award
#IndSwiftLaboratories #INE915B01019 #Award
https://t.co/65mpheu9FT
Ind-Swift Laboratories Ltd posts consolidated PAT of Rs. 25.34 crores in Q2FY23
#IndSwiftLaboratories #Q2FY23 #H1FY23 #ResultUpdate
https://t.co/bVb6zpD7SC
Ind-Swift Laboratories Q3FY22 consolidated net profit drops QoQ to Rs. 16.02 crores
#IndSwiftLaboratories #Q3FY22 #9MFY22 #ResultUpdate
https://t.co/hA96gyy3ud
#StocksInNews
#PI_INDUSTRIES
Executed a Business Transfer Agreement with #IndSwiftLaboratories
For acquisition of their API & Intermediates biz undertaking on a slump sale going concern basis
Acquired business - Rev scale of ~Rs 860 Cr & Margin of ~23%
EV of Rs 1530 Crs
Ind-Swift Laboratories Ltd Q1FY21 net profit higher at Rs. 4.57 crore
#IndSwiftLaboratories #Q1FY21 #ResultUpdate
https://t.co/R8ZTwDIKuT
Ind-Swift Laboratories Ltd posts consolidated profit in Q4 FY2020
#IndSwiftLaboratories #Q4FY20 #FY2020 #ResultUpdate
https://t.co/dhHSxfPGM4
#IndSwiftLaboratories
- The Co. is all set to commercially launch its key API - Fexofenadine in the U.S. Market. Fexofenadine is an antihistamine drug used in the treatment of seasonal allergic Rhinitis and Urticaria in the U.S. market.
– ✅Positive.
#IndSwiftLaboratories
- Fexofenadine, an AntiHistamine Drug used for the treatment of seasonal allergic rhinitis and Urticaria in US market. Company has received the commercial orders and the supplies are beginning from the current quarter.
– ✅Positive.
Ind-Swift Laboratories Ltd to commercially launch key API - Fexofenadine
#IndSwiftLaboratories #API #Fexofenadine
https://t.co/rlL3AfQ8hG
USFDA completes inspection at Ind Swift Laboratories Ltd's API facility
#USFDA #Inspection #Complete #IndSwiftLaboratories #APIfacility
https://t.co/JRNhWwPw7Y
Last Seen Hashtags on Sotwe
KiranRathodhot
Seen from Mexico
snapchat
Seen from Singapore
onlyforfans
Seen from Peru
mlbbnsfw
Seen from Netherlands
minichat
abusekink
Seen from Germany
stefanyaguilar
Seen from Peru
minichat()()()()*+filter:videos
Seen from Singapore
Possession
Seen from Colombia
ageplay Developed
Seen from Brazil
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.4M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
83.9M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers